A Phase II, Randomized, Placebo-Controlled Study to Evaluate the Immunogenicity and the Safety of 2 Schedules of an Homologous Prime-Boost With the ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HIV vaccine vCP1452 (Primary)
Indications HIV infections
Focus Pharmacodynamics; Therapeutic Use
Acronyms MANON-02

Most Recent Events

17 Dec 2009 Actual end date (Sep 2006) added as reported by ClinicalTrials.gov.
11 Jul 2008 Primary endpoint results published in AIDS in July 2008
28 Feb 2007 Results have been reported.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight